Gossamer Bio, Inc. (GOSS) Covered Calls
You can sell covered calls on Gossamer Bio, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for GOSS (prices last updated Fri 4:16 PM ET):
| Gossamer Bio, Inc. (GOSS) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 0.74 | -0.03 | 0.74 | 0.79 | 620K | - | 0.2 |
| Covered Calls For Gossamer Bio, Inc. (GOSS) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Dec 20 | 0.5 | 0.00 | 0.79 | -36.7% | -372.1% | |
| Jan 17 | 0.5 | 0.00 | 0.79 | -36.7% | -209.3% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis both with and without nasal polyps; and in translational Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, selective platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a novel, gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and certain backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was founded in 2015 and is headquartered in San Diego, California.
| Top 10 Open Interest For Dec 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | SAVA covered calls | |
| 2. | SPY covered calls | 7. | XLF covered calls | 2. | RKLB covered calls | |
| 3. | EEM covered calls | 8. | KWEB covered calls | 3. | LUNR covered calls | |
| 4. | FXI covered calls | 9. | TLT covered calls | 4. | NMRA covered calls | |
| 5. | IWM covered calls | 10. | KRE covered calls | 5. | CRVS covered calls | |
Want more examples? GORO Covered Calls | GOVT Covered Calls
